Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

NCT06633835 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT06633835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06633835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Lead sponsor
Novavax
Phase
Phase 4
Overall status
Completed
Start date
September 19, 2024
Completion date
June 30, 2025
Enrollment
660 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars cov 2 infection, vaccine-preventable diseases